Famke Schneiders
@SchneidersFamke
Followers
106
Following
612
Statuses
83
Radiation Oncologist Amsterdam University medical centers @amsterdamumc
Amsterdam, Nederland
Joined December 2017
RT @DrewMoghanaki: The more data I see showing the incredible effectiveness of SBRT, the more I realize the key thing holding back patients…
0
10
0
RT @DrewMoghanaki: A new publication from @max_diehn's group re-demonstrates the utility of ctDNA clearance for personalizing consolidation…
0
24
0
RT @MarkRuffalo: Thank you Javier Bardem for your decency, your courage, and love for all human beings. You are a beacon of light, amigo. h…
0
26K
0
RT @drviviantan: Presented 🚀 MISSILE 🚀 at #ASTRO2024 Combined ☢️ #SABR and 🔪 #surgery in early 🫁 #NSCLC was safe with reasonable clinical…
0
20
0
RT @gerryhanna: Biomarker analysis of I-SABR study by @ASeoMDPhD @ #ASTRO24 🚨Markers of immune activation & exhaustion change dynamically…
0
6
0
RT @DrewMoghanaki: The VALOR study team publishes its' observations evaluating the first 100 participants treated with lung SBRT through 20…
0
30
0
RT @DrewMoghanaki: Throwback to an earlier report showing the risk of false-attributions for local progression after lung SBRT when it’s ju…
0
4
0
RT @DrewMoghanaki: We were reassured by @EnriquetaFelip that with ≥5 years of follow-up, the clinical benefit of postop adjuvant atezolizum…
0
2
0
RT @DrJNaidoo: #ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce…
0
63
0
RT @DrewMoghanaki: Amazing. These outcomes align with the benefit seen with 4 doses of adjuvant Nivo in the phase II randomized I-SABR tria…
0
4
0
RT @DrJNaidoo: #ESMO24 Lung mini-orals🔥 Ph II POTENTIAL trial: 3 doses neoadj Nivolumab in stage I high-risk nsclc: - 52pt academic trial…
0
17
0
RT @DrewMoghanaki: The JCOG 0802 study team reports extraordinarily low rates of incidental LN metastases (1.5%) in part-solid stage IA NSC…
0
9
0
RT @AurelieBruycker: Check out this insightful thread by @DrewMoghanaki highlighting our review providing guidance during post-lung SABR ra…
0
2
0
RT @DrewMoghanaki: How should one act when seeing an "actionable radiological feature"? We're glad you asked. Please see below: https://t.c…
0
4
0
RT @DrewMoghanaki: A new review is published that sheds light on radiographic scars developing after lung SBRT. Caveat: these scars are gen…
0
50
0
RT @TekatliHilal: It's time to use AI-based tools to score treatment-related toxicity after lung radiotherapy. Automated scoring allowed…
0
13
0
@DrCorreaRO @bslotman @amsterdamumc Much appreciated Rohann, it is an honor and a privilege to be involved in this project with such an inspiring team. Great work!
0
0
2